What we study
We apply machine learning to every phase of the clinical trial process — from in-silico cohort simulation and adaptive protocol design through to real-time biomarker monitoring and dropout prediction.
Why it matters
Longevity interventions face a unique challenge: the endpoint — extended healthspan — takes decades to observe. AI lets us design trials around surrogate biomarker endpoints and detect efficacy signals in months rather than years.
Our approach
We build reinforcement learning agents that simulate trial arms, optimise adaptive dosing schedules, and flag safety signals in real time — giving researchers a full AI co-pilot from protocol inception to regulatory submission.